Connect with us

News

Akanda launches new digital dispensing solution in the UK

The first-of-its-kind digital dispensing solution is now live.

Published

on

akanda digital dispensary

A first-of-its-kind fully digital dispensing collaboration for medical cannabis is coming to the UK via a partnership between Akanda, Phlo Connect and Cellen Life Sciences.

Akanda has announced that its UK import and distribution subsidiary CanMart has partnered with Phlo Connect and Cellen Life Sciences to create a fully digital dispensing collaboration for medical cannabis.

The strategic partnership is set to strengthen CanMart’s existing partnership with Cellen’s digital Leva Clinic and expand its route to market in the UK. The dispensing model is fully digital and aims to improve the experience for UK medical cannabis patients.

Phlo Connect integrates digitally with CanMart to deliver prescriptions to patients throughout the United Kingdom. Initially, patients will secure prescriptions through the Leva Clinic, with product transferred through CanMart to Phlo Connect.

Patients can then schedule delivery to their home or office. Phlo Connect is an API-driven digital pharmacy infrastructure provider that connects prescribers, pharmacies and patients for an end-to-end digital experience. Phlo Connect offers a 120-minute delivery service in London and Birmingham and next-day delivery across the UK. The process will be increasingly seamless for patients in the near future as Phlo Connect, Leva Clinic, and CanMart build additional digital interconnections, Akana said.

“Akanda is committed to expanding access to high quality products for anyone in need, and that is qualified in the United Kingdom, a growing market for medical cannabis,” said Tej Virk, CEO of Akanda. “Phlo Connect and Cellen are the ideal partners to make this happen, combining the UK’s first fully digital pharmacy with a digital dispensing model that is easy to use, secure, and real-time.

“In the nascent UK medical cannabis market, patients currently suffer from excess friction as the prescription process, and last mile delivery is disjointed.

“We firmly believe that our solution is the best way to satisfy patients and get our 1P and 3P-supplied medical cannabis in their hands quickly and conveniently, which will greatly improve the patient experience.”

The partnership with Phlo Connect builds on CanMart’s existing partnership with Cellen, a health tech company that provides treatment to chronic pain patients through its digital pain clinic, Leva Clinic, as well as through partners including the NHS, Boots and others.

The Leva Clinic, which is licensed and regulated by the Care Quality Commission (“CQC”), is one of the first fully digital pain clinics in the UK.

The Leva Clinic supports patients through personalised online care plans. Cellen is also a medical cannabis supplier to Project Twenty21, the large-scale medical cannabis observational study monitored by Drug Science that aims to improve access to medical cannabis for those in need.

“We believe partnering with CanMart and Cellen will be a game-changer for medicinal cannabis patients here in the UK. By integrating with both CanMart and Cellen via our API-driven pharmacy platform, we believe that this partnership is the first truly end to end digital experience for medicinal cannabis patients in the UK,” commented Adam Hunter, CCO of Phlo Connect.

“Our patients require access to new high-quality products without the friction and hassle of traditional dispensing services. This partnership is another example of our continuing efforts to build on our national, established relationships with the wider pharmaceutical community in innovative ways. We believe that CanMart’s access to high quality products as well as Phlo Connect’s extensive capabilities in dispensing will go a long way to helping our service to our patients.”

Click to comment

Leave a Reply

Your email address will not be published.

Markets and industry

Medcolcanna signs European medical cannabis sales agreements

The company has entered into sales agreements with German company, Greenstein, and Cantourage.

Published

on

Medcolcanna signs European medical cannabis sales agreements
Home » News » Akanda launches new digital dispensing solution in the UK

Canada-based globally integrated medicinal cannabis company with operations in Colombia, Medcolcanna, has signed two EU Sales agreements for EUGMP and CUMS-IMC certified dried flower.

Medcolcanna has signed agreements with German-based Greenstein, as well as Berlin-based Cantourage.

The sales agreement with German-based Greenstein has a three-year term, with the possibility of extension, and establishes a minimum purchase of 1200 kg during the first year, 2000 kg during the second year and 2,500 kgs during the third year.

Its sales agreement with Cantourage for Germany and the UK has a five-year term, with the possibility of extension. The initial forecast presented by Cantourage establishes approximately 800 – 1000 Kgs for the first year.

Read more: Ugandan-grown medical cannabis reaches UK market

Cantourage will distribute the flower through its proprietary clinics and distribution in the UK and through its network of pharmacies in Germany. Medcolcanna has developed a new brand for distribution with Cantourage in UK and Germany, followed by Poland within the next few months.

Six Medcolcanna proprietary strains have been already registered with the German Narcotics agency, and the production will be based on supply from the Medcolcanna farm located near Bogota. Additionally, THC quotas have been granted by the Colombian Government and are in place with the first exports expected by October to November 2022.

CEO Felipe de la Vega commented: “It has being a long and difficult journey since we created the company. A market that we were trying to understand and anticipate but that was being created. Therefore, making decisions was more complex. 

“CBD market for extracts and isolates became very competitive with the US hemp farm bill affecting projections. The market for THC extracts is highly regulated, requires multiple certifications and a lot of investment, and still is a very small market compared with flower. 

“Now the approval of flower export has allowed us to really gain traction in Colombia supply, as a high quality, low-cost producer, and the result of it is the multiple contracts we have now in place and we continue to negotiate. Starting November 2022, we expect recurrent revenue with high margins and good profitability.

“This combined with internal decisions that have helped us to reduce our G&A and cash burn makes our company a sustainable and profitable target for investors and we are pretty confident that before the end of the year we will be in a completely different situation.

“We continue supplying internally medical formulations currently approximately 300 per month and growing at 15 per cent per month. Now we are really getting to an interesting point for the company, with a very clear path forward and the possibility to generate profits for our investors.”

Continue Reading

Markets and industry

Curaleaf partnership to build platform for German recreational market

The company has entered into a strategic partnership with Germany’s Four 20 Pharma.

Published

on

Curaleaf partnership to build platform for Germany's recreational market
Image credit: artbutenkov
Home » News » Akanda launches new digital dispensing solution in the UK

Curaleaf has acquired a 55 per cent stake in Four 20 Pharma – a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis with its own product line.

Germany currently represents the largest medical cannabis market in Europe, with a total addressable market of over €200m (~£m) in 2022. This is expected to grow to nearly €1bn by the end of 2024 with the expected legalisation of recreational cannabis, expected to begin in late 2023 or early 2024.

Four 20 Pharma is one of the largest cannabis operators in Germany, with a greater than 10 per cent market share.

Read more: Curaleaf is championing social impact in the cannabis industry

The partnership creates a strategic pathway for Curaleaf to acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany. Curleaf has stated that the partnership also ensures alignment between Curaleaf and Four 20 Pharma’s current management team to rapidly build a best-in-class German business and a strong platform for Germany’s eventual adult use market. 

Curaleaf executive chairman, Boris Jordan, commented: “By partnering with Four20 Pharma, Curaleaf’s European business will immediately gain additional critical mass and be in a superior position to capitalise on the accelerating trends in the European cannabis market.

Read more: Curaleaf completes landmark registration of cannabis products in Malta

“The opportunity in Europe cannot be understated, and Curaleaf is uniquely differentiated from other US MSOs via our already significant presence as the largest and most licensed cannabis company in Europe. 

“With cultivation facilities in Portugal, manufacturing facilities in Spain and UK, rapidly growing patient numbers across Europe, particularly in the UK, Curaleaf serves the entire legal cannabis ecosystem and is also poised to capitalise on the adult use opportunity as regulation starts to unlock.

“This strategic transaction further underscores our aspiration to be the major player in the European market and the leading global cannabis company.”

President of Curaleaf International, Miles Worne, said: “Four 20 Pharma is a leading German distributor with a branded product that consumers love. They’ve captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering. 

“As such, Four 20 Pharma is uniquely positioned to capitalise on Germany’s conversion from a medical to an adult use market and we’re thrilled to be partnering with their talented management team.”

Managing Partner of Four 20 Pharma, Torsten Greif, commented: “We have been exploring possible partners to stake our claim in the future German and European cannabis markets, and in Curaleaf we know we’ve found the undisputed leader and the best partner. 

“From the beginning of our conversations, it was clear that they supported our strategic vision and respected our autonomy and entrepreneurial approach. Having full access to the tremendous knowledge and assets of the Curaleaf team will accelerate our future growth projects and help drive our company to the next level.”

Managing partner of Four 20 Pharma, Thomas Schatton, added: “Curaleaf shares our values of customer dedication and commitment to product quality, and we are incredibly excited about our future together. 

“The team at Four 20 are thrilled to be able to leverage Curaleaf’s proven R&D expertise to help us continue delivering the best quality products to our medical patients and the promising future  market.”

Continue Reading

CBD

Tenacious Labs acquires CBD pet company Rover’s Wellness 

The acquisition is part of Tenacious Labs buy-and-build strategy.

Published

on

Tenacious Labs acquires CBD pet company Rover’s Wellness 
Home » News » Akanda launches new digital dispensing solution in the UK

Tenacious Labs has diversified into the pet care market with the acquisition of Rover’s Wellness, which specialises in THC-free CBD.

Tenacious Labs has stated that the acquisition of Rover’s Wellness represents an important milestone in its strategy to become a leading consumer products group globally.

The acquisition sees the group diversify into the high-growth pet care market for the first time. CBD pet care, according to Prohibition Partners, is expected to see global sales of products reach $424.4m (~£350.83) by 2024, representing a CAGR of 18.6 per cent.

Read more: Tenacious Labs to move headquarters to Jersey

As part of the acquisition, RaChelle Baca-Lobre will join Tenacious Labs as global director of sales – pet division and CPG wholesale and private label. Tenacious has stated that Baca-Lobre’s personal passion for CBD-enriched pet care, as well as her experience in managing a fast-growing brand, will prove invaluable for the Group as it looks to scale up its pet care division over the coming months.

Read more: Tenacious Labs CEO discusses its acquisition of Press Pause

 CEO and co-founder of Tenacious Labs, Nicholas Morland, commented: “We are delighted to welcome RaChelle and her team to Tenacious Labs. 

“Since launching in 2018, Rover’s Wellness has grown rapidly, launching genuinely market-leading products which have been well received by customers across the US. This acquisition will enable us to kick-start our pet care division, while combining RaChelle’s expertise and Tenacious Labs’ high quality manufacturing capabilities to significantly scale up Rover’s Wellness. 

“We look forward to working with her closely over the coming months and years.

Tennessee-based Rover’s Wellness creates high quality products containing all natural, non-GMO ingredients including 100 per cent certified organically grown hemp. The company was founded by Baca-Lobre in 2018 after her own pet was diagnosed with cancer. Rover’s Wellness offers a range of oils, topical salves and treats which use CBD to support joint flexibility and mobility, ease anxiety and promote positive long-term health for dogs, cats and equine.

A core part of the brand’s approach is its commitment to testing and transparency. Leveraging a “seed to sale” approach, Rover’s Wellness works directly with growers and uses state-of-the-art nano technology to extract CBD before purity testing. 

Each batch is tested by a certified industrial hemp laboratory, both before and after production, with all lab-results published on its website. This process ensures that none of Rover’s Wellness products contain THC – the psychoactive ingredient in cannabis which is harmful to animals.

Baca-Lobre said: “I am excited to join Tenacious Labs, a group which reflects my desire to create safe, natural and quality products, underpinned by third-party laboratory testing. 

“We have enjoyed great success to date, and I believe that by harnessing Tenacious Labs’ best-in-class manufacturing facilities, marketing expertise, and operational support, we can unlock more exciting growth opportunities for Rover’s Wellness and the group’s broader pet care division.”

Tenacious Labs has now completed three acquisitions since launching 12 months ago, including female-focused CBD brand Press Pause and high-quality white-label manufacturer SZM LLC — now operating as TL Manufacturing. The group has also continued to expand, now employing 35 people around the world as it looks to scale up.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]